Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

An update from Abingdon Health PLC ( ($GB:ABDX) ) is now available. Abingdon Health PLC announced that all resolutions were passed with over 99.7% ...

Abingdon Health PLC Secures Strong Shareholder Support at AGM

Jefferies analyst maintained a Buy rating on Becton Dickinson today and set a price target of $220.00. In addition to Jefferies, Becton Dickinson a...

Jefferies Remains a Buy on Becton Dickinson (BDX)

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics Limited has announced the launch of Avantect® early detectio...

BCAL Diagnostics to Launch Nationwide Cancer Detection Tests in Australia

GSH ( ($SG:BDX) ) just unveiled an announcement. GSH Corporation Limited has secured loan facilities amounting to SGD29 million as per a loan facil...

GSH Corporation Secures SGD29 Million Loan with Shareholder Condition

The latest announcement is out from GSH ( ($SG:BDX) ). GSH Corporation Limited announced that one of its subsidiaries has secured loan facilities a...

GSH Corporation Secures CNH 90 Million Loan with Control Conditions

GSH ( ($SG:BDX) ) has provided an announcement. GSH Corporation Limited held an Extraordinary General Meeting to discuss proposed resolutions, incl...

GSH Corporation Explores New Ventures Amid Shareholder Concerns

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics Limited has achieved a significant milestone with the commercial l...

BCAL Diagnostics Launches Groundbreaking Breast Cancer Detection Test

GSH ( ($SG:BDX) ) has issued an update. GSH Corporation Limited has launched a new series of commercial paper on the SDAX digital securities platfo...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$200.89	+0.23%	2.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$200.89	+0.2%	2.47M
3
4
5
6

BDX

BDX

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel